Truly-4
Truly-4 is a bifunctional Rpn13 PROTAC and CRBN ByeTAC degrader. Degradation of Rpn13 relies on CRBN-mediated E3 ubiquitin ligase activity, while degradation of CRBN itself proceeds via a ByeTAC mechanism of action. Truly-4 induces selective cytotoxicity in hematological cancer cells and solid cancer cells, but not in healthy cells, despite comparable levels of Rpn13 depletion in both cell types. Truly-4 can be used in studies related to B-cell lymphoma and triple-negative breast cancer.
(Pink: Rpn13 ligand (HY-159808); Blue: Cereblon ligand (HY-139539); Black: linker (HY-W008352)).
For research use only. We do not sell to patients.
- Formula: C43H44BrClN8O10S
- Molecular Weight:980.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Cereblon |
In Vitro
Truly-4 (0.5-10 μM; 18 h) induces concentration-dependent degradation of CRBN (via E-ligase-independent ByeTAC mechanism) and Rpn13 (via ubiquitin-dependent PROTAC mechanism) in Ramos B-cell lymphoma cells, with 10 μM treatment reducing CRBN to 48% and Rpn13 to 35% of baseline levels after 18 h[1].
Truly-4 (0.5-10 μM; 18 h) induces concentration-dependent degradation of CRBN and Rpn13 in MDA-MB-468 triple-negative breast cancer cells, with 10 μM treatment reducing CRBN to 56% and Rpn13 to 39% of baseline levels after 18 h[1].
Truly-4 (0.001-100 μM; 48 h) induces selective cytotoxicity in Ramos B-cell lymphoma and MDA-MB-468 triple-negative breast cancer cells after 48 h incubation, with no significant toxicity observed in HEK-293T or MRC-5 nonmalignant cells[1].
Truly-4 (0.5-10 μM; 18 h) induces concentration-dependent degradation of Rpn13 but does not degrade CRBN in HEK-293T nonmalignant cells, with CRBN levels remaining stable or slightly elevated[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Ramos B-cell lymphoma suspension cells
-
Concentration:0.5, 1 and 10 μM (18 h incubation); 10 μM (18 h incubation with co-reagents); 25 μM (2 h co-immunoprecipitation; 18 h incubation with pre-treatment reagents); 10 μM (4, 8, 48 h time-course)
-
Incubation Time:18 h (0.5-10 μM; 10 μM with co-reagents; 25 μM with pre-treatment reagents); 2 h (25 μM co-immunoprecipitation); 4, 8, 48 h (10 μM time-course)
-
Result:Reduced CRBN levels to 88% and Rpn13 levels to 76% of baseline at 0.5 μM.
Reduced CRBN to 52% and Rpn13 to 60% of baseline at 1 μM.
Reduced CRBN to 48% and Rpn13 to 35% of baseline at 10 μM.
Fully abrogated degradation of both CRBN and Rpn13 when co-treated with 20 nM proteasome inhibitor MG-132.
Rescued Rpn13 degradation but did not affect CRBN degradation when co-treated with 10 nM ubiquitin-activating enzyme inhibitor TAK-243 or 10 nM NEDD8-activating enzyme inhibitor MLN4924.
Increased ubiquitinated Rpn13 levels by 51% relative to control at 25 μM.
Blocked CRBN degradation but modestly enhanced Rpn13 degradation when pre-treated with 25 μM Rpn2 peptide.
Attenuated degradation of both proteins when pre-treated with 25 μM TCL1 or immunomodulatory imide drug thalidomide.
Induced rapid and sustained degradation of both proteins over 48 h in time-course experiments.
-
Cell Line:MDA-MB-468 triple-negative breast cancer adherent cells
-
Concentration:0.5, 1 and 10 μM
-
Incubation Time:18 h
-
Result:Reduced CRBN levels to 72% and Rpn13 levels to 61% of baseline at 0.5 μM.
Reduced CRBN to 65% and Rpn13 to 64% of baseline at 1 μM.
Reduced CRBN to 56% and Rpn13 to 39% of baseline at 10 μM.
-
Cell Line:HEK-293T nonmalignant adherent cells
-
Concentration:0.5, 1 and 10 μM
-
Incubation Time:18 h
-
Result:Reduced Rpn13 levels to 71% of baseline (CRBN levels remained at 100%) at 0.5 μM.
Reduced Rpn13 to 51% of baseline (CRBN levels increased to 117%) at 1 μM.
Reduced Rpn13 to 49% of baseline (CRBN levels increased to 112%) at 10 μM.
-
Cell Line:Ramos B-cell lymphoma, MDA-MB-468 triple-negative breast cancer, HEK-293T nonmalignant, MRC-5 nonmalignant fibroblast cells
-
Concentration:0.001, 0.1, 1, 10 and 100 μM
-
Incubation Time:48 h
-
Result:Induced potent cytotoxicity in Ramos and MDA-MB-468 cancer cells, with viability dropping to near 0% at 100 μM.
Caused no measurable loss of viability in HEK-293T and MRC-5 nonmalignant cells even at the highest concentration tested.
Chemical Information
-
Molecular Weight 980.28
-
Formula C43H44BrClN8O10S
-
SMILES
O=C(NCCOCCOCCOCCOCCNC(C1=CC2=C(C(N(C2=O)C3CCC(NC3=O)=O)=O)C=C1)=O)CC4SC5=NN=C(N5N=C4C6=CC=C(C=C6)Cl)CC7=CC=C(C=C7)Br
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)